Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.51 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690794 | 0.80 | PROKR1 (0.51) | PROKR1 | |
| SCHEMBL26729833 | 0.78 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL30469804 | 0.78 | CHRNB4 (0.58) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL32688969 | 0.78 | RBP4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4PROKR1 | |
| SCHEMBL31578358 | 0.77 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL19205428 | 0.76 | RBP4 (0.57) | PROKR1 | |
| SCHEMBL19205395 | 0.76 | RBP4 (0.59) | PROKR1 | |
| SCHEMBL19205350 | 0.76 | RBP4 (0.59) | PROKR1 | |
| SCHEMBL26209110 | 0.76 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL19205310 | 0.75 | RBP4 (0.60) | PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |